The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 2×
“Consequently, it is likely that the anti-convulsant effects of CBD described above arise via cannabinoid receptorindependent mechanisms.(22,27,28)”
BackgroundAgonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Overview of the voltage-gated sodium channel family
Yu (2003) · Genome biology · doi:10.1186/gb-2003-4-3-207 · Cited by 694 · cited 1×
“In contrast, all AEDs licensed for clinical use in the UK cause significant and strong motor side-effects emphasising the advantage of CBD as a potential clinical anti-convulsant.(52)”
BackgroundCannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608 · cited 1×
“It is already well known that CBD has only very low affinity for both endogenous CB1 and CB2 receptors 7,20,21 and is therefore likely to be exerting its anti-convulsant activity via cannabinoid receptor-independent mechanisms.(17,22,23) Thus far, CBD has shown a poly-pharmacological profile, potentially modulating ne…”
BackgroundCarrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · cited 2×
“Moreover, numerous additional cellular and molecular CBD effects and mechanisms of action have also been proposed, but are less likely to be related to CBD’s anti-convulsant profile but, for example, have pharmacological relevance in CNS disorders, pain, inflammation and cancer (reviewed in Hill et al.(24) and Izzo et…”
BackgroundSelf-citation
Cited by
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000
“CBD also exerted anticonvulsant effects against PTZ-induced acute generalized seizures, pilocarpineinduced temporal lobe convulsions, and penicillin-induced partial seizures inWistar-Kyoto rats.(34,35)”
BackgroundSelf-citationCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 521
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Metadata
- Authors
- Jones, N. A., Glyn, S. E., Akiyama, S., Hill, T. D. M., Hill, A. J., Weston, S. E., Burnett, M. D. A., Yamasaki, Y., Stephens, G. J., Whalley, B. J., & Williams, C. M.
- Venue
- Seizure
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 21
- Issue
- 5
- Pages
- 344-352
- ISSN
- 1059-1311 (ISSN-L)
- OpenAlex
- W2122465097
- Cited by
- 248
- References
- 6
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.